ISSCR News


The ISSCR Launches Standards Initiative for Pluripotent Stem Cell Research
Policy Keith Alm Policy Keith Alm

The ISSCR Launches Standards Initiative for Pluripotent Stem Cell Research

Universally accepted characterization standards for stem cell research are needed to improve the rigor and reproducibility of stem cell research. Standards set researchers up for success, ensure rigor in preclinical research, and ultimately strengthen the pipeline of therapies for patients. As the foremost international stem cell research society with a reputation for scientific and ethical rigor, the ISSCR is uniquely positioned to develop and propose research standards that can be widely adopted worldwide.

Read More
Advocating for Regulations that Facilitate Safe and Efficacious Therapies

Advocating for Regulations that Facilitate Safe and Efficacious Therapies

Last December, nearly 40 professionals with the U.S. Food and Drug Administration (FDA) gathered with ISSCR leaders to discuss advances in the development of stem cell therapies. The attendance of FDA leaders – Peter Marks, Director, Center for Biologics Evaluation and Research (CBER), Celia Witten, Deputy Director, CBER, and Wilson Bryan, Director, Office of Tissues and Advanced Therapies (OTAT) – signals how important it is for the agency to discuss scientifically informed recommendations from the ISSCR as new stem cell-based therapies advance.

Read More

Receive ISSCR Press Releases

Sign up be a part of ISSCR’s media list. Media Contact: Kym Kilbourne, Director of Media and Strategic Communications

Subscribe to ISSCR News.

Each month, ISSCR delivers scientific, policy, and community to your inbox .